Up-regulated LINC01234 promotes non-small-cell lung cancer cell metastasis by activating VAV3 and repressing BTG2 expression
Open Access
- 20 January 2020
- journal article
- research article
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 13 (1), 1-14
- https://doi.org/10.1186/s13045-019-0842-2
Abstract
Long noncoding RNAs (lncRNAs) are known to regulate tumorigenesis and cancer progression, but their contributions to non-small-cell lung cancer (NSCLC) metastasis remain poorly understood. Our previous and other studies have revealed the involvement of upregulated LINC01234 in regulating gastric cancer and colon cancer cells proliferation, and we aimed to investigate whether LINC01234 overexpression also contribute to cancer cells metastasis in this study. We collect the NSCLC tissues and adjacent non-tumor tissues and analyzed expression levels of LINC01234 by quantitative reverse-transcription PCR. LINC01234 were knocked down by using siRNAs or shRNAs, and overexpressed by transfection with overexpression vector; RNA levels of miRNA were downregulated or upregulated with inhibitors or mimics. Transwell assays were used to evaluate cell migration and invasive ability; in vivo metastasis experiments were performed to investigate the effect of LINC01234 on NSCLC cells metastasis. Luciferase reporter, RIP, and ChIP assays were used to determine the regulation of LINC01234 on its targets. LINC01234 expression is increased in NSCLC tissues, and its upregulation is associated with metastasis and shorter survival in NSCLC. Downregulation of LINC01234 impairs cell migration and invasion in vitro, and inhibits cells metastasis in vivo by acting as a competing endogenous RNA for the miR-340-5p and miR-27b-3p. LINC01234 also interacts with the RNA-binding proteins LSD1 and EZH2, leading to histone modification and transcriptional repression of the anti-proliferative genes BTG2. Taken together, our findings identify two oncogenic regulatory axes in NSCLC centering on LINC01234: one involving miR-340-5p/miR-27b-3p in the cytoplasm and the second involving EZH2, LSD1, and BTG2 in the nucleus. Our study indicates that these genes may be targeted to reduce or prevent NSCLC metastasis.Keywords
Funding Information
- National Natural Science Foundation of China (81871871, 81902333, 81602013, 81802275, 81703056)
This publication has 35 references indexed in Scilit:
- MET As a Possible Target for Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2013
- KRAS Mutation: Should We Test for It, and Does It Matter?Journal of Clinical Oncology, 2013
- Control of somatic tissue differentiation by the long non-coding RNA TINCRNature, 2012
- The GENCODE pseudogene resourceGenome Biology, 2012
- GENCODE: The reference human genome annotation for The ENCODE ProjectGenome Research, 2012
- Vav3-Rac1 Signaling Regulates Prostate Cancer Metastasis with Elevated Vav3 Expression Correlating with Prostate Cancer Progression and Posttreatment RecurrenceCancer Research, 2012
- Breast tumor progression induced by loss of BTG2 expression is inhibited by targeted therapy with the ErbB/HER inhibitor lapatinibOncogene, 2011
- Targeted therapy in non-small-cell lung cancer—is it becoming a reality?Nature Reviews Clinical Oncology, 2010
- EML4-ALKFusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung CancerClinical Cancer Research, 2008
- Mapping of Small RNAs in the Human ENCODE RegionsAmerican Journal of Human Genetics, 2008